SK chemicals(CEO, vice chairman, Chang-Geun Kim) declared November 1st(11/1), the sale date, as [the erection day in the world] by commemorating the sale of Mvix, the strongest erectile dysfunction treating medicine in the world.

In-Seok Lee, marketing headquarters manager of life science parts at SK chemicals, announced that November 1st(11/1), which is triple 1, is declared as [the erection day in the world], meaning [completion of male] because number 1 means [male] and number 3 means [completion] and [male’s sexual organs] according to Freud’s psychology, and was determined as the sale date of Mvix, the 1st ranking in International Index of Erection Function.

Mvix (mirodenafil 2HCL 100mg) started to be developed jointly in 1998 by SK chemicals and IN2GEN, a bio venture, went through a pre-clinical demonstration in 2003, the 1st phase clinical demonstration(Covance in Britain) in 2004, the 2nd phase clinical demonstration in March 2005 and the 3rd phase clinical demonstration in March 2006 successfully, acquired [approval of product items for manufacturing medicines] from KFDA on July 18, 2007, and then was acknowledged as the 13th new medicine in Korea.

Mvix acquired 25.7 points(26 or more points of IIEF EF index are a [normal erection] level), the highest points in history, out of possible 30 full points in the International Index of Erection Function(IIEF EF) measurement, an international index to show the medicine efficacy of an erectile dysfunction treating medicine, showed less headache occurring when depressing PDE-1 and PDE-6 because of having high selectivity* for PDE-5 as compared with existing competitive products such as Viagra, etc., and has been known to be excellent in safety because no color vision trouble* has been reported.

Jae-Seung Baek, professor at Seoul National University having lead the clinical demonstration of Mvix, expressed, “according to the 3rd phase clinical demonstration results carried out for 223 persons at 15 general hospitals in Korea such as Seoul National University Hospital, etc., Mvix recorded 91.95% vagina permeation rate, 73.20% sexual intercourse completion rate and 89.04% total satisfaction level with 100mg, and showed remarkable improvement of satisfaction levels about overall life along with sexual life, partner relationships and home life in terms of life satisfaction levels.”

Overall market size of domestic erectile dysfunction treating medicine was 64 billion won in 2004, 70.5 billion won in 2005 and 77 billion won in 2006, recording high growth rates of over 10% every year, and Mvix is expecting 10 billion won revenue in 2008, the realistic first year of sale.

Gwang-Seok Lee, assistant manager, PM of Mvix, announced, “in the future, SK chemicals will be positively advertising the strong erectile dysfunction treating effect of 1st ranking of IIEF(International Index of Erection Function) and the safety of medicines verified by clinical demonstrations through symposiums, etc.”

Meanwhile, SK chemicals has completed registration of a Chinese trademark name(愛比獅 aibishi) in order to advance into the Chinese erectile dysfunction treating medicine market of 450 billion won(4 billion RMB) size, is proceeding with local marketing through SK Pharma Beijing (Beijing, Tianjin, Shanghai), an affiliate, is securing an intellectual property right by registering/ applying a substance patent to 38 nations over the world such as United States, EU, China, Japan, etc., and is promoting technology export together to major nations such as China, etc. simultaneously with sale in Korea.

SK chemicals has become a life science enterprise holding 3 new medicines developed by itself for the first time in Korea by succeeding in the development of Mvix this year after success in development of anticancer medicine[Sunpla], the 1st new medicine in Korea, in 1999 and development of arthritis medicine[Joins], the 1st natural new medicine in Korea, in 2001, and is planning to contribute to the enhancement of health and happiness of human kinds through continuous development of new medicines in the future.

........................................................................................................................................